INTUITIVE SURGICAL INC quarterly report, Q1 FY2014

Business context and reporting period

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci robotic surgical systems, instruments and accessories, and related services. This unaudited Form 10-Q covers the three months ended March 31, 2014; comparisons are with the first quarter of 2013 unless noted. The company launched its fourth-generation da Vinci Xi system in the U.S. in April 2014.

Financial results and liquidity

Revenue fell 24%, operating income fell 77%, and net income fell 77%. Product revenue was $360.8 million, including $106.0 million of system revenue and $254.8 million of instruments and accessories. Service revenue rose 10% to $103.9 million. Recurring revenue was $358.7 million, or 77% of revenue. The company reported no debt in the presented balance sheet. At March 31, current assets were $2.078 billion and current liabilities were $459.5 million; total liabilities were $537.6 million.

Operating cash flow was lower than the prior year, while investing activities used $205.3 million and financing activities provided $70.6 million. Cash and cash equivalents increased $31.9 million during the quarter. Cash, cash equivalents and investments rose $209.7 million from year-end 2013. The company said it expects current liquidity and operating cash generation to fund requirements for the foreseeable future. It had $708.5 million of cash, cash equivalents and investments held by foreign subsidiaries and said it did not plan to repatriate those earnings.

Material changes versus prior period

• System revenue declined 59% to $106.0 million; shipments fell to 87 systems from 164. Management cited moderating procedure growth, hospital capital-spending pressures, and anticipation of the Xi system. U.S. shipments were 45 versus 115.
• Total da Vinci procedures grew approximately 7%, compared with 18% in Q1 2013. Growth in U.S. general surgery and international urology was partly offset by declines in U.S. gynecologic and urologic procedures.
• Instruments and accessories revenue fell 2%, while service revenue increased 10%, reflecting the larger installed base. The installed base reached 3,039 systems.
• SG&A rose 53% to $215.8 million, chiefly including a $67.4 million product-liability charge. Excluding the overall revenue and expense changes, reported operating profitability was also affected by lower product gross margin, product mix, and lower system production volume.
• Cash from operations decreased from $258.0 million to $166.3 million. The 2014 quarter had no share repurchases; Q1 2013 financing included $145.7 million of repurchases.

Outlook, commentary, risks and unusual items

The filing provides no specific numerical revenue or earnings guidance. Management expects substantial ongoing investment in procedure adoption, product development and commercial operations, and expects R&D expense to continue increasing. Future system demand is subject to procedure growth, hospital economics, regulatory clearances, and reimbursement developments. Management noted that U.S. benign gynecology procedures declined at a low-single-digit rate year over year in Q1; U.S. prostatectomy procedures were about 5% lower.

• Trade-in deferrals: In connection with the Xi launch, certain Q1 Si purchasers were offered credits toward Xi systems. The company deferred $25.6 million of revenue and $6.1 million of related costs for estimated returns; it anticipated recognizing deferred revenue upon shipment and customer acceptance, substantially by June 30, 2014.
• Product liability: The $67.4 million accrual relates to estimated resolution costs for claims involving alleged complications associated with certain Monopolar Curved Scissor instruments and tip-cover accessories. Approximately 83 individual product-liability lawsuits were pending, and about 3,000 claims had been reviewed in mediation. The company said additional loss beyond the accrual was reasonably possible but could not estimate a range; actual costs could materially exceed the estimate.
• Regulatory and reputation: The FDA issued a warning letter in 2013 and, after a February–March 2014 inspection, identified five quality-system observations. The company submitted a corrective-action plan. Negative media coverage, litigation, and adverse-event reporting could delay adoption or affect system sales and revenue. The company stated that reported adverse events do not necessarily establish device causation.
• Other uncertainties: The filing identifies healthcare spending and reimbursement, competition, product acceptance, regulatory approvals, manufacturing, foreign-market expansion, litigation, and seasonality as risks. No additional Japanese procedure reimbursements were granted in the April 2014 cycle. The company also cited uncertainty following the FDA’s April 2014 statement discouraging power morcellators, which could affect decisions about minimally invasive fibroid procedures.
• The company reported a 26.8% effective tax rate; the U.S. federal R&D tax credit had expired at year-end 2013 and was not reflected in Q1 2014 tax expense. It reported $75.9 million of gross unrecognized tax benefits.

Important facts for investors to verify

• Whether the $25.6 million Xi-related revenue deferral was recognized as anticipated, and the resulting effect on subsequent revenue and margins.
• Whether system shipments and procedure growth recover, especially in U.S. gynecology and urology, and how the Xi launch affects demand and pricing.
• Whether the $67.4 million product-liability accrual proves adequate; the filing could not estimate potential losses above the amount recorded.
• Progress on FDA corrective actions and the effect of regulatory scrutiny, adverse-event reporting, and media coverage on adoption and sales.
• Cash generation and investment balances, including the availability and tax implications of funds held by foreign subsidiaries.